dronedarone / Generic mfg. - LARVOL DELTA

Identification of cellular ion channels that facilitate Hazara nairovirus infection enables selection of clinically approved compounds with anti-nairoviral properties. (PubMed, Sci Rep) - "Consistent with this, we showed that clinically-approved K+ channel blockers quinidine, quinine and dronedarone and clinically-approved Ca2+ channel blockers tetrandrine and nifedipine significantly reduced HAZV activities. Biochemical experiments showed K+ expanded the pH range that promoted entry, potentially allowing endosome escape deeper within the endolysosomal network. These results show clinically-approved channel blockers effectively inhibit HAZV replication, suggesting repurposing existing therapies may represent promising avenues to block nairovirus infection."

Journal • Infectious Disease

Efficacy and Safety of Dronedar one in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial. (PubMed, J Cardiovasc Electrophysiol) - P3 | "Dronedarone is an effective AAD for patients with AF across a range of BMI categories with a manageable safety profile."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Obesity

Pharmacologic rhythm control for atrial fibrillation with dronedarone versus sotalol in patients with and without heart failure. (PubMed, Curr Probl Cardiol) - No abstract available

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

CONTINUATION VERSUS INTERRUPTION OF MAINTENANCE ANTIARRHYTHMIC THERAPY IN ADULT INTENSIVE CARE UNIT PATIENTS (ACC 2026) - "Background: For patients admitted to an intensive care unit (ICU), there is limited guidance regarding the management of maintenance antiarrhythmic drug (AAD) therapy such as flecainide, propafenone, dofetilide, dronedarone, and sotalol...For patients who developed unstable arrhythmias, acute treatment with direct current cardioversion (DCCV) or pharmacological therapy, such as amiodarone, beta or non-dihydropyridine calcium channel blockers, or digoxin, will be recorded... Research is currently ongoing with the objective of gaining insight to prescribing patterns and clinical outcomes."

Clinical • Cardiovascular • Critical care • Ventricular Tachycardia

ABLATION OF INTRA-ATRIAL REENTRANT TACHYCARDIA WITHIN THE LATERAL TUNNEL IN A PATIENT WITH FONTAN CIRCULATION (ACC 2026) - "Sotalol was precluded by prolonged QTc interval and dronedarone was trialed...Amiodarone was initiated; however, long term therapy was felt unfavorable due to younger age and co-existing liver disease... Patients with Fontan circulation have a proclivity for atrial arrhythmias, and AV dyssynchrony is poorly tolerated compared to two ventricle circulations. This case presents an example of successful intra-tunnel ablation of IART in a IALT Fontan with closed fenestrations."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hepatology

PREPROCEDURAL CLASS III ANTIARRHYTHMIC THERAPY AND CONDUCTION DISTURBANCES AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) (ACC 2026) - "The effect of class III antiarrhythmic drugs (AADs; sotalol, amiodarone, dronedarone and dofetilide) on these complications remains unclear. Pre-procedural class III AAD use was associated with reduced new-onset AF following TAVI but did not significantly influence conduction disturbances or PPM implantation. Further prospective studies are needed to clarify their role in optimizing post-TAVI outcomes."

Atrial Fibrillation • Cardiovascular

Repurposing dronedarone induces ferroptosis through GPX4 inactivation and degradation in pancreatic cancer. (PubMed, J Exp Clin Cancer Res) - No abstract available

Journal • Oncology • Pancreatic Cancer • Solid Tumor • GPX4

Delayed Recognition of Dronedarone-Induced Interstitial Lung Disease in a Patient with Membranous Nephropathy on Immunosuppression (NKF-SCM 2026) - "Dronedarone, a benzofuran antiarrhythmic structurally related to amiodarone, has been linked to rare pulmonary toxicity...METHODS/CASE SUMMARY A 73-year-old man with biopsy-confirmed MN on prednisone and repository corticotropin (ACTH) presented with 2 weeks of worsening dyspnea and cough...Dronedarone was discontinued, and high‑dose intravenous methylprednisolone was started...This effect can be masked by immunosuppressive agents used in many conditions, delaying timely recognition, as in this case. Clinicians should consider routine pulmonary surveillance in high‑risk patients to enable earlier detection."

Clinical • Cough • Glomerulonephritis • Interstitial Lung Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases

EAST-STROKE: Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke (clinicaltrialsregister.eu) - P4 | N=1035 | Recruiting | Sponsor: University Medical Center Hamburg-Eppendorf

New P4 trial • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Bioequivalence Study of Dronedarone Hydrochloride Tablets (clinicaltrials.gov) - P=N/A | N=48 | Completed | Sponsor: Shandong New Time Pharmaceutical Co., LTD

New trial • Atrial Fibrillation • Cardiovascular

Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions (clinicaltrials.gov) - P=N/A | N=51 | Completed | Sponsor: Shandong New Time Pharmaceutical Co., LTD

New trial • Atrial Fibrillation • Cardiovascular

Factors influencing the inappropriate dosing of rivaroxaban and edoxaban in Chinese hospitalized patients with atrial fibrillation. (PubMed, Front Cardiovasc Med) - "Inappropriate dosing of direct oral anticoagulants (DOACs) may increase the risk of thromboembolism or bleeding in patients with atrial fibrillation (AF). The incidence of inappropriate DOAC dosing in Chinese patients with AF was high. Advanced age, the concurrent use of antiplatelet medications, and the nonuse of dronedarone have been identified as independent factors associated with inappropriate dosing."

Journal • Atrial Fibrillation • Cardiovascular

New recommendations for rhythm control-What has changed in the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines for atrial fibrillation, and where does dronedarone fit in? (PubMed, Am Heart J Plus) - "Since the last major review of the efficacy and safety of dronedarone (published in 2019), multiple real-world evidence (RWE) studies and post hoc analyses of key dronedarone randomized controlled trials have been performed. This review discusses the findings of these RWE studies and post hoc analyses in the context of the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines for AF with a focus on dronedarone as a treatment option for early rhythm control, its use after catheter ablation, and its use in people with heart failure and a mildly reduced or preserved ejection fraction."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Marked QTc Interval Prolongation Associated With Dronedarone in Paroxysmal Atrial Fibrillation and No Structural Disease. (PubMed, Cureus) - "Dronedarone, a multichannel antiarrhythmic drug, was developed as a safer alternative to amiodarone for atrial fibrillation. We describe the case of a 44-year-old male with paroxysmal atrial fibrillation and no structural heart disease who developed marked QTc prolongation while receiving dronedarone, despite being asymptomatic. This case highlights the potential for clinically silent but significant QTc prolongation during dronedarone therapy, underscoring the importance of careful ECG monitoring, even in low-risk patients."

Journal • Atrial Fibrillation • Cardiovascular • Heart Failure

Repurposing dronedarone for colorectal cancer therapeutic via suppression of the AKT/ERK signaling pathways. (PubMed, Biochem Pharmacol) - "Mechanically, dronedarone and D4 induced mitochondrial dysfunction and suppressed both AKT (protein kinase B) and ERK (extracellular regulated protein kinase) signaling pathways simultaneously leading to CRC cells apoptosis. Collectively, our study sheds light on repurposing non-oncology drug dronedarone and its derivatives with their molecular mechanisms for CRC treatment."

Journal • Colorectal Cancer • Metabolic Disorders • Oncology • Solid Tumor

Discovery, development, and characterization of potent and selective USP11 inhibitors. (PubMed, Pharmacol Res) - "RBF4, chemically identical to the FDA-approved anti-arrhythmic agent Dronedarone, exhibits potent antitumor efficacy in orthotopic EμMyc lymphoma models, suppressing tumor growth, metastatic spread, and ascites formation with no overt toxicity...RBF4 emerges as a clinically actionable prototype for dismantling USP11-driven oncogenic circuits, illuminating a new therapeutic axis in lymphoid malignancies and beyond. ONE SENTENCE SUMMARY: Potent, selective USP11 inhibitors exhibit anti-tumor activity."

Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Targeted Protein Degradation • USP11

Dronedarone synergizes with colistin against planktonic and biofilm forms of multidrug-resistant Gram-negative pathogens. (PubMed, Microbiol Spectr) - "Because dronedarone has a known safety record in people, this approach could be developed more quickly than entirely new antibiotics. These findings highlight a practical strategy to repurpose existing medicines to strengthen current antibiotics and fight life-threatening, drug-resistant infections."

Journal • Infectious Disease • Pneumonia

Clinical and Economic Outcomes of Dronedarone Versus Amiodarone Among Patients With Atrial Fibrillation. (PubMed, J Am Heart Assoc) - "In this study, lower event/incidence rates of AEs and health care resource use were observed in patients with atrial fibrillation treated with dronedarone versus amiodarone."

HEOR • Journal • Atrial Fibrillation • Cardiovascular

DRIVE-AF: Dronedarone Rhythm Intervention for Early Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1898 | Not yet recruiting | Sponsor: Inha University Hospital

HEOR • New P4 trial • Atrial Fibrillation • Cardiovascular

Impact of Dronedarone on Early Recurrence After Catheter Ablation in Patients With Nonparoxysmal Atrial Fibrillation. (PubMed, Cardiovasc Ther) - "In this retrospective study of patients with nonparoxysmal atrial fibrillation after catheter ablation, dronedarone and amiodarone showed a trend toward better efficacy than propafenone in preventing overall early recurrence. Dronedarone demonstrated a specific advantage in preventing early recurrence of atrial flutter."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against Clostridioides difficile. (PubMed, Int J Antimicrob Agents) - "In a time-kill assay, DRO outperformed the approved drugs, vancomycin (VAN) and fidaxomicin (FDX), reducing the high bacterial inoculum below the limit of detection within 2 h. Additionally, both drugs were more effective than VAN at preventing the formation and germination of C. difficile spores. Our findings suggest that these antiarrhythmic drugs have potential as compelling lead molecule for CDI drug discovery, warranting further investigation and potentially paving the way for new anti-C. difficile therapies."

Journal • Preclinical • Infectious Disease

Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with non-valvular atrial fibrillation: a multinational cohort study. (PubMed, BMC Med) - "Concomitant use of interacting antiarrhythmic drugs does not seem to affect the effectiveness of DOACs but may increase their risk of major bleeding."

Journal • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Exploratory high-throughput screening of repurposed drugs for canine lymphoid malignancies. (PubMed, BMC Vet Res) - "This exploratory screening study identified clinically approved drugs with available pharmacokinetic data as candidate therapeutic agents for the treatment of canine lymphoid malignancies. Based on this study, further studies are warranted to validate the in vivo efficacy and elucidate the underlying mechanisms of candidate drugs in canine lymphoid malignancies."

Journal • Hematological Malignancies • Lymphoma • Oncology

Dronedarone hydrochloride targets cardiolipin and phosphatidylglycerol to increase colistin susceptibility in gram-negative pathogens. (PubMed, Microbiol Spectr) - "Mechanistic studies revealed that DH bound specifically to CL and PG, thereby enhancing membrane disruption, impairing energy production, and stimulating oxidative stress levels, which collectively augment the bactericidal activity of colistin. These findings present DH as a lead compound for combating colistin resistance, while offering novel mechanistic insights into its role as a colistin potentiator."

Journal • Infectious Disease

Embryotoxicity analysis of anti-arrhythmia drugs amiodarone, dronedarone, and their metabolites using 3D gastruloid models. (PubMed, Reprod Toxicol) - "The study also provided mechanistic and human-relevant insights not attainable through traditional animal testing. Our findings underscore the utility of stem cell-based models for assessing human developmental toxicity, and support their use in evaluating safer alternatives for anti-arrhythmic therapy during pregnancy."

Adverse events • Journal • Cardiovascular • Heart Failure